Biontech (BNTX) Stock Price
Biontech Price
Biontech (BNTX) Stock | ISIN US09075V1026 | WKN A2PSR2. The current Biontech stock price is 88.08 EUR (2026). Revenue is 2.7 B EUR. Net income is -861.56 M EUR. The P/E ratio is -24.58. Market capitalization is 21.17 B EUR. Biontech operates in the Health sector.
Biontech stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biontech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biontech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biontech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biontech Price |
|---|
Biontech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biontech Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M EUR) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M EUR) |
| NET INCOME (M EUR) |
| NET INCOME GROWTH (%) |
| DIVIDEND (EUR)DIV. (EUR) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biontech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biontech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biontech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biontech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biontech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biontech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biontech Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biontech business model & stock analysis
Biontech SWOT Analysis
Strengths
BioNTech has a strong research and development team consisting of highly skilled scientists and experts in the field of biotechnology. This expertise enables the company to develop innovative solutions and make advancements in the biopharmaceutical industry.
The company has established strategic partnerships with pharmaceutical giants such as Pfizer, which provides BioNTech with resources, distribution networks, and access to global markets. This collaboration leverages the strengths of both companies, leading to increased market presence and accelerated commercialization of products.
BioNTech has successfully developed and gained regulatory approval for its mRNA-based COVID-19 vaccine, which has positioned the company as a key player in the fight against the pandemic. This breakthrough achievement has enhanced BioNTech's reputation and increased investor confidence in the company.
Weaknesses
As a relatively young company, BioNTech has a limited product portfolio compared to established competitors in the industry. This narrow product range makes the company susceptible to market fluctuations and increased competition.
BioNTech's reliance on external funding for its research and development activities poses a potential weakness. The company heavily depends on grants, collaborations, and partnerships, which may expose it to financial uncertainties and restricted control over decision-making processes.
Opportunities
The growing demand for personalized medicine and advancements in mRNA technology present significant opportunities for BioNTech. The company can further explore and develop mRNA-based therapies for various diseases, expanding its product pipeline and addressing unmet medical needs.
BioNTech can leverage its expertise in mRNA technology to collaborate with other pharmaceutical companies, universities, and research institutions. By entering into partnerships or licensing agreements, the company can access new markets, diversify its revenue streams, and accelerate the development of innovative therapies.
Threats
Intense competition within the biopharmaceutical industry poses a threat to BioNTech. Established companies and emerging players are investing heavily in research and development, potentially leading to the introduction of competing products that could impact BioNTech's market share.
The regulatory environment and potential changes in government policies related to healthcare and drug approvals could pose risks for BioNTech. Changes in regulations or delays in obtaining regulatory approvals may hinder the company's ability to bring its products to market in a timely manner.
Biontech Eulerpool Fair Value
Biontech historical P/E ratio, EBIT multiple, and P/S ratio
Biontech annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biontech shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Biontech Dividend History
1 years of dividend payments
Biontech dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Biontech Earnings Estimates
Biontech Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/5/2026 | -2.26EUR | 173.23 MEUR | 2026 Q1 |
| 3/10/2026 | -0.04EUR | 810.4 MEUR | 2025 Q4 |
| 5/6/2024 | 0.71EUR | 1.08 BEUR | 2024 Q1 |
| 3/25/2024 | 2.44EUR | 2.16 BEUR | 2023 Q4 |
| 8/7/2023 | 2.68EUR | 2.12 BEUR | 2023 Q2 |
| 5/8/2023 | 4.58EUR | 3.06 BEUR | 2023 Q1 |
| 3/28/2023 | 7.59EUR | 3.95 BEUR | 2022 Q4 |
| 11/7/2022 | 4.6EUR | 2.1 BEUR | 2022 Q3 |
| 8/8/2022 | 7.22EUR | 3.94 BEUR | 2022 Q2 |
| 5/9/2022 | 9.34EUR | 4.4 BEUR | 2022 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Biontech stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Biontech shareholder structure
| % | Name |
|---|---|
42.36795% | |
16.69205% | |
3.2776% | |
2.90289% | |
1.75961% | |
1.6645% | |
1.52178% | |
1.49687% | |
0.85289% | |
0.62647% |
Biontech Executives and Management Board
Prof. Ugur Sahin
(59)Chief Executive Officer, Member of the Management Board
Mr. Ryan Richardson
(45)Chief Strategy Officer, Member of the Management Board
Dr. Sierk Poetting
(50)Chief Operating Officer, Member of the Management Board
Dr. Oezlem Tuereci
(56)Chief Medical Office, Member of the Management Board
Ms. Annemarie Hanekamp
(44)Member of the Management Board, Chief Commercial Officer
Biontech Supply Chain
Frequently asked questions about Biontech
BioNTech SE is primarily active in the biotechnology and pharmaceutical industries.
Biontech stock
Biontech Peer Group
Biontech Ticker
Biontech FIGI
All fundamentals and in-depth analysis of Biontech
Our stock analysis for Biontech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biontech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.